Famotidine augmentation in schizophrenia: Hope or hype?

Journal of Clinical Psychiatry

Volumn 74, Issue 9, 2013, Pages

  Andrade, Chittaranjan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ASENAPINE; CLOZAPINE; FAMOTIDINE; HALOPERIDOL; HISTAMINE H2 RECEPTOR; LAMOTRIGINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO;

ARTICLE; BLOOD BRAIN BARRIER; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG SAFETY; HUMAN; NEGATIVE SYNDROME; PEPTIC ULCER; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 84884758673     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13f08707     Document Type: Article

References (25)

1. Arrang JM. Histamine and schizophrenia. Int Rev Neurobiol. 2007;78:247-287. doi:10.1016/S074-742(06)7809-6 PubMed
2. Meskanen K, Ekelund H, Laitinen J, et al. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2013;33(4) 472-478 doi:10.1097/JCP.0b013e3182970490 PubMed
3. Chremos AN. Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol. 1987;9(suppl 2):7-12. doi:10.1097/04836-19870702-03 PubMed
4. Langtry HD, Grant SM, Goa KL. Famotidine: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989;38(4):551-590. doi:10.2165/03495-198938040-05 PubMed
5. Kaminsky R, Moriarty TM, Bodine J, et al. Effect of famotidine on deficit symptoms of schizophrenia. Lancet. 1990;335(8701):1351-1352. doi:10.1016/0140-6736(90)91237-5 PubMed
6. Rosse RB, Kendrick K, Tsui LC, et al. Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. Clin Neuropharmacol. 1995;18(4):369-374. doi:10.1097/02826-195080-09 PubMed
7. Deutsch SI, Rosse RB, Kendrick KA, et al. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol. 1993;16(6):518-524. doi:10.1097/02826-193120-05 PubMed
8. Whiteford HA, Stedman TJ, McGrath JJ, et al. An open-label study of famotidine as a treatment for schizophrenia. J Psychiatry Neurosci. 1995;20(3):239-240. PubMed
9. Oyewumi LK, Vollick D, Merskey H, et al. Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatry Neurosci. 1994;19(2):145-150. PubMed
10. Rosenberg PB, Rosse RB, Johri SK, et al. Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report. Clin Neuropharmacol. 1996;19(3):276-281. doi:10.1097/02826-19619030-01 PubMed
11. Rosse RB, Kendrick K, Fay-McCarthy M, et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol. 1996;19(4):341-348. doi:10.1097/02826-19619040-07 PubMed
12. Dannon P, Lepkifker E, Iancu I, et al. Famotidine: a supplemental drug for the treatment of schizophrenia. Eur Psychiatry. 1997;12(5):263-264. doi:10.1016/S0924-938(97)8302-0
13. Abhari SAA, Mohtasham S. Clinical trial of H2 blocker: augmentation treatment of schizophrenia. Andeesheh va Raftar. 2000;5(3):10-17.
14. Poyurovsky M, Tal V, Maayan R, et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol. 2004;14(4):332-336. doi:10.1016/j.euroneuro.203.10.04 PubMed
15. Farzin D, Hosseini SH, Shafaat A. A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia. Iran J Med Sci. 2005;30(2):59-62.
16. Humbert-Claude M, Davenas E, Gbahou F, et al. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl). 2012;220(1):225-241. doi:10.107/s0213-01-2471-5 PubMed
17. Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73.
18. Alvarez FJ, Casas E, Franganillo A, et al. Effects of antidepressants on histamine H2 receptors in rat isolated uterus. J Pharmacol. 1986;17(3):351-354. PubMed
19. Goodman WK, Charney DS. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. J Clin Psychiatry. 1985;46(10 pt 2):6-24. PubMed
20. Orsulak PJ, Waller D. Antidepressant drugs: additional clinical uses. J Fam Pract. 1989;28(2):209-216. PubMed
21. Alvarez FJ, Velasco A, Palomares JL. Blockade of muscarinic, histamine H1 and histamine H2 receptors by antidepressants. Pharmacology. 1988;37(4):225-231. doi:10.159/0138470 PubMed
22. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia [published online ahead of print July 3, 2013]. Int J Neuropsychopharmacol. 2013;1-12. doi:10.1017/ S146145713067 PubMed
23. Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatmentresistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry. 2003;54(11):1241-1248. doi:10.1016/S06-323(03)0524-9 PubMed
24. Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry. 2004;56(6):441-446. doi:10.1016/j.biopsych.204.06.029 PubMed
25. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol. 2007;27(6):582-589.